Document Detail


Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
MedLine Citation:
PMID:  22537438     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recently developed drugs and innovative strategies for the treatment of chronic infection with genotype 1 hepatitis C virus (HCV) have become the standard of care. The protease inhibitors telaprevir (Incivek) and boceprevir (Victrelis) are the first direct-acting antiviral (DAA) agents approved, and many more are being developed. These drugs substantially increased rates of sustained virologic response in treatment-naïve and -experienced patients, in conjunction with peginterferon and ribavirin (triple therapy), in phase 3 trials. The efficacy of triple therapy depends on appropriate selection of patients, although the population of patients that receive triple therapy could be expanded as the risk/benefit ratio improves. Attention to details that reflect the standard of care, such as appropriate dosing, anticipation of adverse effects, and strict adherence to stopping rules, will insure the success of these drugs and lead the way for new combination therapies.
Authors:
A Sidney Barritt; Michael W Fried
Related Documents :
22913318 - Targeting the pregnane x receptor in liver injury.
22367108 - In vitro release profile of anti-ulcer drug rabeprazole from biocompatible psyllium-pva...
22310528 - Hollow spherical mesoporous phosphosilicate nanoparticles as a delivery vehicle for an ...
22866958 - Clinical review: volume of fluid resuscitation and the incidence of acute kidney injury...
6841958 - Comparative activity of anticestode drugs--praziquantel, niclosamide and compound 77-6,...
6926538 - Studies on the cause of hyperuricosuria in cystic fibrosis patients.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Gastroenterology     Volume:  142     ISSN:  1528-0012     ISO Abbreviation:  Gastroenterology     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-27     Completed Date:  2012-06-18     Revised Date:  2014-03-21    
Medline Journal Info:
Nlm Unique ID:  0374630     Medline TA:  Gastroenterology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1314-1323.e1     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Hypochromic / chemically induced
Antiviral Agents / administration & dosage,  adverse effects,  pharmacology,  therapeutic use*
Clinical Trials as Topic
Drug Administration Schedule
Drug Eruptions / etiology
Drug Interactions
Drug Therapy, Combination
Gastrointestinal Tract / drug effects
Hepacivirus / drug effects*,  genetics
Hepatitis C, Chronic / drug therapy*
Humans
Interferon-alpha / administration & dosage,  adverse effects,  therapeutic use*
Oligopeptides / administration & dosage,  adverse effects,  therapeutic use*
Polyethylene Glycols / administration & dosage,  adverse effects,  therapeutic use*
Proline / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Recombinant Proteins / administration & dosage,  adverse effects,  therapeutic use
Ribavirin / administration & dosage,  adverse effects,  therapeutic use*
Serine Proteinase Inhibitors / therapeutic use
Treatment Outcome
Grant Support
ID/Acronym/Agency:
1KL2-RR025746-03/RR/NCRR NIH HHS; K24 DK066144/DK/NIDDK NIH HHS; K24 DK066144/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 0/N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; 0/Oligopeptides; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/Serine Proteinase Inhibitors; 0/peginterferon alfa-2a; 0/telaprevir; 49717AWG6K/Ribavirin; 9DLQ4CIU6V/Proline
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New virologic tools for management of chronic hepatitis B and C.
Next Document:  Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antiv...